Pieris Pharmaceuticals (NASDAQ:PIRS) & Evelo Biosciences (NASDAQ:EVLO) Head-To-Head Comparison

Risk & Volatility

Evelo Biosciences has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Insider and Institutional Ownership

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 6.4% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Evelo Biosciences and Pieris Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Pieris Pharmaceuticals	-39.71%	-80.93%	-59.55%

Valuation & Earnings

This table compares Evelo Biosciences and Pieris Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53 million	($13.29)	0.00
Pieris Pharmaceuticals	$20.87 million	1.00	-$24.54 million	($12.10)	-1.31

Pieris Pharmaceuticals has higher revenue and earnings than Evelo Biosciences. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

About Evelo Biosciences

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.